article thumbnail

STAT+: Sanders blames food companies for diabetes epidemic

STAT

Sanders held a hearing today on diabetes that implicated both the food and drug industries in what the American Diabetes Association estimates is a $413 billion annual cost to the health care system. WASHINGTON — Sen. Bernie Sanders (I-Vt.) has a new corporate target: the food industry.

Diabetes 345
article thumbnail

STAT+: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds

STAT

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. As a result, they don’t reduce health care spending — they drive it up.

Diabetes 356
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Type 2 diabetes prevention programs can work at large scale, study finds

STAT

LONDON — Clinical trials have shown that lifestyle programs — which include diet, exercise, and behavioral coaching — can help people in danger of developing type 2 diabetes from tipping into a diagnosis of the condition. A study published Wednesday backs up the idea that they can. Read the rest…

Diabetes 312
article thumbnail

STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows

STAT

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Diabetes 363
article thumbnail

STAT+: FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia

STAT

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Diabetes 356
article thumbnail

STAT+: Patients loved Carbon Health’s diabetes program. That couldn’t save it

STAT

A diabetes diagnosis was not what Jason had in mind when he set out on a cross-country road trip with his family in the fall of 2021. He went to get checked out at the Palo Alto Medical Foundation, and on a Thursday night in November, the blood test results popped up in his patient portal: He had type 2 diabetes.

Diabetes 295
article thumbnail

STAT+: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study

STAT

GSBR-1290, taken once daily, belongs to the booming class of GLP-1 drugs that increase insulin production to lower blood sugar in people with diabetes and make people feel full after eating, leading to dramatic weight loss in people with obesity. discontinuation rate that could prove to be an advantage if confirmed in larger studies.

Diabetes 307